PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Saver, Jeffrey L.
TI  - Addition of AMPLATZER PFO Occluder to Medical Therapy is Beneficial in Patients with Cryptogenic Stroke and PFO
DP  - 2013 May 01
TA  - MD Conference Express
PG  - 18--19
VI  - 13
IP  - 1
4099  - http://mdc.sagepub.com/content/13/1/18.short
4100  - http://mdc.sagepub.com/content/13/1/18.full
AB  - Cryptogenic stroke remains a major challenge for clinicians taking care of patients who have had strokes. Patent foramen ovale (PFO) is a contributor to cryptogenic stroke due to paradoxical embolism [Furlan AJ et al. N Engl J Med 2012], but the optimal management strategy for PFO has yet to be defined [Kitsios GD et al. Stroke 2012]. This article reports the results of a follow-up analysis of the RESPECT PFO Clinical Trial [RESPECT; NCT00465270] to characterize the qualifying and endpoint ischemic strokes.